79570-19-7 (brimonidine tartrate,5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate)

酒石酸溴莫尼定;酒石酸溴莫尼定 BRIMONIDINE TARTRATE;

brimonidine tartrate;5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate;AGN-190342-LF;UK-14304-18;Alphagan P;Alphagan;5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine D-tartrate;BRIMONIDINE-D-TARTRATE;brimonidine Purite;BRIMONIDINE TARTRATE (EP MONOGRAPH);BRIMONIDINE TARTRATE [JAN];Brimonidine tartarate;BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8%;BRIMONIDINE TARTRATE [EP MONOGRAPH];UK 14,304 (tartrate);6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1);Qoliana;LUMIFY Redness Reliever Eye Drops;70359-46-5;AGN 190342LF;5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate (1:1);CD-07805/47;MFCD07773072;DTXSID70911371;(2R,3R)-2,3-dihydroxybutanedioic acid; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;79570-19-7;CCG-221278;Brimonidinne tartrate;5-bromo-N-;Brimonidine tartrate (JAN/USAN);mirvaso;BRIMONIDINE TARTRATE [WHO-DD];UNII-4S9CL2DY2H;BRIMONIDINE TARTRATE (USP-RS);AGN-190342LF;Brimonidine tartrate [USAN];5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid;HY-B0659A;BRIMONIDINE TARTRATE COMPONENT OF COMBIGAN;6-Quinoxalinamine, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-,(2R,3R)-2,3-dihydroxybutanedioate(1:1);CS-4496;(4,5-Bihydro-1H-imidazol-2-yl)quinoxalin-6-amine L-tartrate;5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine(2R,3R)-2,3-dihydroxysuccinate;CD07805/47;BRIMONIDINE TARTRATE [MART.];Brimonidine Tartrate ophthalmic solution, 0.15%;AGN 190342-LF;5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine tartrate;QZHBYNSSDLTCRG-LREBCSMRSA-N;BRIMONIDINE TARTRATE [VANDF];5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine mono-(2R,3R)-tartrate;SCHEMBL265607;BRIMONIDINE D-TARTRATE [MI];(5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1h-imidazol-2-yl)-amine L-tartrate;BRIMONIDINE TARTRATE [USP MONOGRAPH];OCU-300;DTXCID501340408;Cd-07805;BRIMONIDINE TARTRATE (MART.);BRIMONIDINE TARTRATE COMPONENT OF SIMBRINZA;AS-18083;Brimonidine L-Tartrate;4S9CL2DY2H;Brimonidine tartrate [USAN:JAN];EX-A5415A;HMS3715P18;D02076;BRIMONIDINE TARTRATE [USP-RS];AKOS016845265;Alphagan (TN);OCU300;BRIMONIDINE TARTRATE (USP MONOGRAPH);109826-56-4;UK-1430418;SIMBRINZA COMPONENT BRIMONIDINE TARTRATE;Alphagan-P;BRIMONIDINE TARTRATE [ORANGE BOOK];Lumify;Brominide tartrate;6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1);5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate;CHEMBL1200389;Bromoxidine tartrate;COMBIGAN COMPONENT BRIMONIDINE TARTRATE;L(+)-TARTARIC ACID; BRIMONIDINE;

QZHBYNSSDLTCRG-LREBCSMRSA-N

1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

BrC1C2C(C=CC=1NC1=NCCN1)=NC=CN=2.O[C@@H](C(=O)O)[C@H](C(=O)O)O